Advertisement

Investigational New Drugs

, Volume 25, Issue 3, pp 279–281 | Cite as

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel

  • Stephan A. VeltkampEmail author
  • Jetske M. Meerum Terwogt
  • Michel M. van den Heuvel
  • Hester H. van Boven
  • Jan H. M. Schellens
  • Sjoerd Rodenhuis
Case Report

Introduction

Gemcitabine/docetaxel (G/D) combination therapy has shown favourable response rates in patients with leiomyosarcoma (LMS) [1, 2, 3]. Although, G/D treatment is generally well tolerated, it can cause side effects, such as myelosuppression and fatigue.

We describe two out of nine patients with advanced LMS, refractory to doxorubicin who developed acute pulmonary toxicity after treatment with 3-weekly gemcitabine 900 mg/m2 as 90-min infusion on day 1 and 8 followed by docetaxel 100 mg/m2 as 60-min infusion on day 8 and s.c. pegfilgrastim on day 9.

Case 1

A 67-year old woman presented with intra-abdominal metastasis from recurrent LMS of the ovary. G/D treatment was started. After the second cycle some lesions had regressed. After the fourth cycle she complained of fatigue and developed a dry cough. Chemotherapy was discontinued, however, she became progressively more dyspnoeic and hypoxic. She was afebrile and on ausculatation she had normal breathing sounds. Her haemoglobin...

Keywords

Pulmonary toxicity Gemcitabine Docetaxel Leiomyosarcoma 

References

  1. 1.
    Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831PubMedCrossRefGoogle Scholar
  2. 2.
    Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH (2004) Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22:1706–1712PubMedCrossRefGoogle Scholar
  3. 3.
    Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Blay JY (2006) Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 119:706–711PubMedCrossRefGoogle Scholar
  4. 4.
    Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44:363–368PubMedCrossRefGoogle Scholar
  5. 5.
    Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL (2006) Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 106:2051–2057PubMedCrossRefGoogle Scholar
  6. 6.
    Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J, Lewsley L, Coleman R, Reed NS, Kaye S, Rustin GJ (2006) SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer 94:62–68PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Stephan A. Veltkamp
    • 1
    • 2
    Email author
  • Jetske M. Meerum Terwogt
    • 2
  • Michel M. van den Heuvel
    • 2
  • Hester H. van Boven
    • 3
  • Jan H. M. Schellens
    • 1
    • 2
    • 4
  • Sjoerd Rodenhuis
    • 2
  1. 1.Division of Experimental TherapyThe Netherlands Cancer Institute/Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  2. 2.Department of Medical OncologyThe Netherlands Cancer Institute/Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  3. 3.Department of PathologyThe Netherlands Cancer Institute/Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  4. 4.Division of Biomedical Analysis, Faculty of Pharmaceutical SciencesUniversity of UtrechtUtrechtThe Netherlands

Personalised recommendations